Epidermal growth factor receptor signaling in the kidney key roles in physiology and disease

Hypertension

Volumn 52, Issue 6, 2008, Pages 987-993

  Melenhorst, Wynand B W H ^a   Mulder, Gemma M ^a   Xi, Qi ^b   Hoenderop, Joost G J ^b   Kimura, Keita ^c   Eguchi, Satoru ^c   Van Goor, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; RAPAMYCIN;

ELECTROLYTE BALANCE; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; ORGANOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; TISSUE DISTRIBUTION;

ANIMALS; HUMANS; HYPERTENSION, RENAL; KIDNEY; KIDNEY DISEASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 57449108683     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.113860     Document Type: Short Survey

References (71)

1. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol. 2004;44:195-217.
2. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res. 2004;94:68-76.
3. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis. 2006;186:38-53.
4. Sweeney C, Carraway KL III. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene. 2000;19:5568-5573.
5. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM. Shedding light on ADAM metalloproteinases. Trends Biochem Sci. 2005;30:413-422.
6. Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol. 2006;291:C1-C10.
7. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med. 2005;11:867-874.
8. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40.
9. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependem, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem. 2005;280:26592- 26599.
10. Soond SM, Everson B, Riches DW, Murphy G. ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci. 2005;118:2371-2380.
11. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science. 1995;269:230-234.
12. Bernardini N, Bianchi F, Lupetti M, Dolfi A. Immunohistochemical localization of the epidermal growth factor, transforming growth factor alpha, and their receptor in the human mesonephros and metanephros. Dev Dyn. 1996;206:231-238.
13. Nakanishi K, Sweeney W Jr, Avner ED. Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease. J Am Soc Nephrol. 2001;12:379-384.
14. Zeng F, Zhang MZ, Singh AB, Zent R, Harris RC. ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. Mol Biol Cell. 2007;18:4446-4456.
15. Carev D, Saraga M, Saraga-Babic M. Expression of intermediate filaments, EGF and TGF-alpha in early human kidney development. J Mol Histol. 2008;39:227-235.
16. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999;98:663-673.
17. Sakurai H, Tsukamoto T, Kjelsberg CA, Cantley LG, Nigam SK. EGF receptor ligands are a large fraction of in vitro branching morphogens secreted by embryonic kidney. Am J Physiol. 1997;273:F463-F472.
18. Kim HS, Kim MS, Hancock AL, Harper JC, Park JY, Poy G, Perantoni AO, Cam M, Malik K, Lee SB. Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem. 2007;282:16278- 16287.
19. Sakurai H, Nigam SK. In vitro branching tubulogenesis: implications for developmental and cystic disorders, nephron number, renal repair, and nephron engineering. Kidney Int. 1998;54:14-26.
20. Rogers SA, Ryan G, Hammerman MR. Metanephric transforming growth factor-alpha is required for renal organogenesis in vitro. Am J Physiol. 1992;262:F533-F539.
21. Yosypiv IV, Schroeder M, El-Dahr SS. Angiotensin II type 1 receptor-EGF receptor cross-talk regulates ureteric bud branching morphogenesis. J Am Soc Nephrol. 2006;17:1005-1014.
22. Harris RC. Potential physiologic roles for epidermal growth factor in the kidney. Am J Kidney Dis. 1991;17:627-630.
23. Kuper C, Bartels H, Fraek ML, Beck FX, Neuhofer W. Ectodomain shedding of pro-TGF-alpha is required for COX-2 induction and cell survival in renal medullary cells exposed to osmotic stress. Am J Physiol Cell Physiol. 2007;293:C1971-C1982.
24. Singh AB, Sugimoto K, Dhawan P, Harris RC. Juxtacrine activation of EGFR regulates claudin expression and increases transepithelial resistance. Am J Physiol Cell Physiol. 2007;293:C1660-C1668.
25. Tong Q, Stockand JD. Receptor tyrosine kinases mediate epithelial Na(+) channel inhibition by epidermal growth factor. Am J Physiol Renal Physiol. 2005;288:F150-F161.
26. Stein-Oakley AN, Tzanidis A, Fuller PJ, Jablonski P, Thomson NM. Expression and distribution of epidermal growth factor in acute and chronic renal allograft rejection. Kidney Int. 1994;46:1207-1215.
27. Groenestege WM, Thebault S, van der WJ, van den BD, Janssen R, Tejpar S, van den Heuvel LP, Van CE, Hoenderop JG, Knoers NV, Bindels RJ. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260-2267.
28. Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA. Magnesium transport in the renal distal convoluted tubule. Physiol Rev. 2001;81:51-84.
29. Schlingmann KP, Weber S, Peters M, Niemann NL, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002;31:166-170.
30. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, Hoenderop JG. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem. 2004;279:19-25.
31. Sontia B, Montezano AC, Paravicini T, Tabet F, Touyz RM. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. Hypertension. 2008;51:915-921.
32. Thebault S, Alexander RT, Groenestege WM, Hoenderop JG, Bindels RJ. EGF activates TRPM6 via a Src kinase and Rac1 mediated increase in plasma membrane expression. J Am Soc Nephrol. In press.
33. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, Van CE. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8:387-894.
34. Melenhorst WB, van den Heuvel MC, Timmer A, Huitema S, Bulthuis M, Timens W, van Goor H. ADAM19 expression in human nephrogenesis and renal disease: Associations with clinical and structural deterioration. Kidney Int. 2006;70:1269-1278.
35. Yoshioka K, Takemura T, Murakami K, Akano N, Matsubara K, Aya N, Maki S. Identification and localization of epidermal growth factor and its receptor in the human glomerulus. Lab Invest. 1990;63:189-196.
36. Nakopoulou L, Stefanaki K, Boletis J, Papadakis J, Kostakis A, Vosnides G, Zeis PM. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol Dial Transplant. 1994;9:764-769.
37. Sis B, Sarioglu S, Celik A, Zeybel M, Soylu A, Bora S. Epidermal growth factor receptor expression in human renal allograft biopsies: an immunohistochemical study. Transpl Immunol. 2004;13:229-232.
38. Takemura T, Murata Y, Hino S, Okada M, Yanagida H, Ikeda M, Yoshioka K. Heparin-binding EGF-like growth factor is expressed by mesangial cells and is involved in mesangial proliferation in glomerulonephritis. J Pathol. 1999;189:431-438.
39. Solari V, Shima H, Puri P. Increased expression of EGFR and TGF-alpha in segmental renal dysplasia in duplex kidney. Pediatr Surg Int. 2004;20:243-247.
40. Lee DC, Chan KW, Chan SY. Expression of transforming growth factor alpha and epidermal growth factor receptor in adult polycystic kidney disease. J Urol. 1998;159:291-296.
41. Chertin B, Farkas A, Puri P. Epidermal growth factor and monocyte chemotactic peptide-1 expression in reflux nephropathy. Eur Urol. 2003;44:144-149.
42. Teteris SA, Menahem SA, Perry G, Maguire JA, Dowling JP, Langham RG, Thomson NM, Stein AN. Dysregulated growth factor gene expression is associated with tubulointerstitial apoptosis and renal dysfunction. Kidney Int. 2007;71:1044-1053.
43. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, Friedlander G. Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest. 2000;106:225-234.
44. Francois H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, Chatziantoniou C. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J. 2004;18:926-928.
45. Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int. 2004;66:1805-1814.
46. Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, Avner ED. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest. 1998;101:935-939.
47. Sweeney WE Jr, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003;64:1310-1319.
48. Wilson SJ, Amsler K, Hyink DP, Li X, Lu W, Zhou J, Burrow CR, Wilson PD. Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia. Biochim Biophys Acta. 2006;1762:647-655.
49. Wang Z, Chen JK, Wang SW, Moeckel G, Harris RC. Importance of functional EGF receptors in recovery from acute nephrotoxic injury. J Am Soc Nephrol. 2003;14:3147-3154.
50. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2006;26:e133-e137.
51. Che Q, Carmines PK. Angiotensin II triggers EGFR tyrosine kinase-dependent Ca2+ influx in afferent arterioles. Hypertension. 2002;40:700-706.
52. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation. 2002;106:909-912.
53. Jamroz-Wisniewska A, Wojcicka G, Lowicka E, Ksiazek M, Beltowski J. Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: role in leptin-induced hypertension. Biochem Pharmacol. 2008;75:1623-1638.
54. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation. 2005;112:423-431.
55. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, Dussaule JC. Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J. 2003;17:327-329.
56. Park JK, Fischer R, Dechend R, Shagdarsuren E, Gapeljuk A, Weimer M, Meiners S, Gratze P, Al-Saadi N, Feldt S, Fiebeler A, Madwed JB, Schirdewan A, Haller H, Luft FC, Muller DN. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007;49:481-489.
57. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A, Maruyama K, Masaki H, Shibasaki Y, Fujiyama S, Nose A, Iba O, Hasagawa T, Tateishi E, Higashiyama S, Iwasaka T. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int. 2001;60:2153-2163.
58. Chen J, Chen JK, Neilson EG, Harris RC. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol. 2006;17:1615-1623.
59. Zhuang S, Dang Y, Schnellmann RG. Requirement of the epidermal growth factor receptor in renal epithelial cell proliferation and migration. Am J Physiol Renal Physiol. 2004;287:F365-F372.
60. Zhuang S, Kinsey GR, Rasbach K, Schnellmann RG. Heparin-binding epidermal growth factor and Src family kinases in proliferation of renal epithelial cells. Am J Physiol Renal Physiol. 2008;294:F459-F468.
61. Zhuang S, Yan Y, Daubert RA, Schnellmann RG. Epiregulin promotes proliferation and migration of renal proximal tubular cells. Am J Physiol Renal Physiol. 2007;293:F219-F226.
62. Spix JK, Chay EY, Block ER, Klarlund JK. Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res. 2007;313:3319-3325.
63. Mishra R, Leahy P, Simonson MS. Gene expression profiling reveals role for EGF-family ligands in mesangial cell proliferation. Am J Physiol Renal Physiol. 2002;283:F1151-F1159.
64. Humes HD, Cieslinski DA, Coimbra TM, Messana JM, Galvao C. Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest. 1989;84:1757-1761.
65. Singh AB, Sugimoto K, Harris RC. Juxtacrine activation of epidermal growth factor (EGF) receptor by membrane-anchored heparin-binding EGF-like growth factor protects epithelial cells from anoikis although maintaining an epithelial phenotype. J Biol Chem. 2007;282:32890-32901.
66. Chevalier RL, Goyal S, Thornhill BA. EGF improves recovery following relief of unilateral ureteral obstruction in the neonatal rat. J Urol. 1999;162:1532-1536.
67. Harris RC. Growth factors and cytokines in acute renal failure. Adv Ren Replace Ther. 1997;4:43-53.
68. Hise MK, Salmanullah M, Liu L, Drachenberg CI, Papadimitriou JC, Rohan RM. Control of the epidermal growth factor receptor and its ligands during renal injury. Nephron. 2001;88:71-79.
69. Kiley SC, Thornhill BA, Belyea BC, Neale K, Forbes MS, Luetteke NC, Lee DC, Chevalier RL. Epidermal growth factor potentiates renal cell death in hydronephrotic neonatal mice, but cell survival in rats. Kidney Int. 2005;68:504-514.
70. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50:203-218.
71. Mir O, Berveiller P, Ropert S, Goffinet F, Pons G, Treluyer JM, Goldwasser F. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol. 2008;19:607-613.